Abstract:Abstract Objective: The programmed death-1/programmed death-1 ligands (PD-1/PD-Ls) pathway is critical for attenuating autoimmunity and maintaining T cell homeostasis. It has been suggested that PD-1/PD-Ls plays an important role in tumor evasion from host immunity. Although strong evidence supports the concept of immunosurveillance and immunoediting in colorectal cancer, the immune regulatory role of PD-1/PD-Ls pathway is not clear in colorectal cancer (CRC) patients. Here we investigated the expression of PD-1 and the soluble ligands (sPD-Ls) in blood plasma of patients with inflammatory Bowel Disease (IBD) and CRC. Methods: Age-matched 107 health controls, 109 patients with colorectal cancer and 109 patients with IBD from West China Hospital (Chengdu, Sichuan, China.) were enrolled in the present study. The levels of PD-1 and sPD-Ls in blood plasma were analyzed by enzyme linked immunosorbent assay (ELISA). Expression of PD-L1 and PD-L2 were investigated in colorectal tissue by immunohistochemical (IHC) staining. Results: The level of PD-1 in the plasma of the CRC patients was significantly up-regulated compared with healthy people (P=0.004), but there was no significant difference between IBD patient and healthy people. The levels of PD-1 were higher in CRC patients than in IBD patients. The levels of PD-L1 and soluble PD-L2 in peripheral blood were significantly increased in CRC patients comparing to health patients (P=0.0028 and p=0.0264, respectively). sPD-Ls were correlated with circulatory PD-1 expression in the CRC patients. These results indicated that the PD-1/PD-Ls pathway is activated in the CRC patients. However, we didn't observe significant differences either between IBD patients and healthy people or between CRC patients and IBD patients. We further confirmed that PD-L1 and PD-L2 were localized in colorectal cancer cells by IHC. In 67 CRC patients, the positive rates of PD-L1 and PD-L2 were 35.3% and 65%, respectively. In addition, expression of PD-1, PD-L1 and PD-L2 were higher in the patients with metastatic CRC compared to the patients with primary CRC. Conclusion: The higher levels of plasma sPD-Ls may be associated with CRC and may predict CRC metastatic progression. The existence of immunosuppressive PD-1 and sPD-Ls in the circulation of CRC patients may indicate that PD-Ls suppress immune responses against CRC not only locally, but also systemically. This information will provide a novel insight into the role of PD-1/PDLs in CRC-mediated immunosuppression. Citation Format: Jipei Du, Yao Cheng, Zhigang Mao, Shiping Liao, Yanjiang Zheng, Ji Zhang, Yufang Wang. Upregulation of soluble programmed death ligands in patients with colorectal cancer. [abstract]. In: Proceedings of the CRI-CIMT-EATI-AACR Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival; September 16-19, 2015; New York, NY. Philadelphia (PA): AACR; Cancer Immunol Res 2016;4(1 Suppl):Abstract nr A004.

ZG16 regulates PD-L1 expression and promotes local immunity in colon cancer

Loss of ZG16 is Regulated by Mir-196A and Contributes to Stemness and Progression of Colorectal Cancer

ZG16 enhances the maturation of dendritic cells via induction of CD40 and contributes to the antitumor immunity in pancreatic cancer

MPDZ is associated with immune infiltration and regulates migration and invasion by switching YAP1 phosphorylation in colorectal cancer

Knockdown of NDRG1 Promote Epithelial-Mesenchymal Transition of Colorectal Cancer Via NF-κB Signaling.

ANGPTL1 Attenuates Colorectal Cancer Metastasis by Up-Regulating Microrna-138

Overexpression of ZNF169 promotes the growth and proliferation of colorectal cancer cells via the upregulation of ANKZF1

KRT17 Promotes T-lymphocyte Infiltration Through the YTHDF2-CXCL10 Axis in Colorectal Cancer

Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling

USP18 Is Associated with PD-L1 Antitumor Immunity and Improved Prognosis in Colorectal Cancer

MGP Promotes CD8+ T Cell Exhaustion by Activating the NF-κB Pathway Leading to Liver Metastasis of Colorectal Cancer

Abstract A004: Upregulation of Soluble Programmed Death Ligands in Patients with Colorectal Cancer

Abstract 1688: Nuclear receptor coactivator SRC-1 promotes colorectal cancer immune escape by enhancing PD-L1 transcription and protein stability

ZNF516 suppresses stem cell-like characteristics by regulating the transcription of Sox2 in colorectal cancer.

Mucin 16 Promotes Colorectal Cancer Development and Progression Through Activation of Janus Kinase 2

PD-L1 Restrains the PD-1hiNrp1loTGFβ+ Treg to block IL6+ Neutrophil tumor infiltration to Suppress Inflammation-driven Colorectal Cancer

Zinc finger protein 671 has a cancer-inhibiting function in colorectal carcinoma via the deactivation of Notch signaling

Region‐Specific CD16+ Neutrophils Promote Colorectal Cancer Progression by Inhibiting Natural Killer Cells

Downregulation of GRHL2 inhibits the proliferation of colorectal cancer cells by targeting ZEB1.

Significance of Siglec‐15 Expression in Colorectal Cancer: Association with Advanced Disease Stage and Fewer Tumor‐infiltrating Lymphocytes

Association of CD8+TILs co-expressing granzyme A and interferon-γ with colon cancer cells in the tumor microenvironment